WO2002085300A3 - Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts - Google Patents

Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts Download PDF

Info

Publication number
WO2002085300A3
WO2002085300A3 PCT/US2002/012814 US0212814W WO02085300A3 WO 2002085300 A3 WO2002085300 A3 WO 2002085300A3 US 0212814 W US0212814 W US 0212814W WO 02085300 A3 WO02085300 A3 WO 02085300A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
interleukin
physiological processes
pulmonary fibroblasts
assessment
Prior art date
Application number
PCT/US2002/012814
Other languages
French (fr)
Other versions
WO2002085300A2 (en
Inventor
Min Huang
Sherven Sharma
Raj K Batra
Robert M Strieter
Steven M Dubinett
Michael P Keane
Original Assignee
Univ California
Min Huang
Sherven Sharma
Raj K Batra
Robert M Strieter
Steven M Dubinett
Michael P Keane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Min Huang, Sherven Sharma, Raj K Batra, Robert M Strieter, Steven M Dubinett, Michael P Keane filed Critical Univ California
Priority to AU2002307497A priority Critical patent/AU2002307497A1/en
Publication of WO2002085300A2 publication Critical patent/WO2002085300A2/en
Publication of WO2002085300A3 publication Critical patent/WO2002085300A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Abstract

The invention is based on the disclosure provided herein on the finding that the cytokine interleukin-7 (IL-7) limits the development of pulmonary fibrosis in clinically relevant models of idiopathic pulmonary fibrosis (IPF). As illustrated below, the disclosure provides additional information relating to the specific cellular mechanisms involved in this pathology and provides models for the assessment of different therapeutic modalities employing IL-7 as well as the assessment of new therapeutic agents and methods for the treatment of this syndrome.
PCT/US2002/012814 2001-04-23 2002-04-23 Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts WO2002085300A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002307497A AU2002307497A1 (en) 2001-04-23 2002-04-23 Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US28593301P 2001-04-23 2001-04-23
US60/285,933 2001-04-23
US28625701P 2001-04-24 2001-04-24
US60/286,257 2001-04-24

Publications (2)

Publication Number Publication Date
WO2002085300A2 WO2002085300A2 (en) 2002-10-31
WO2002085300A3 true WO2002085300A3 (en) 2003-09-25

Family

ID=26963474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/012814 WO2002085300A2 (en) 2001-04-23 2002-04-23 Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts

Country Status (2)

Country Link
AU (1) AU2002307497A1 (en)
WO (1) WO2002085300A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
NZ597098A (en) 2006-09-28 2013-05-31 Merck Sharp & Dohme Use of pegylated il-10 to treat cancer
EP2986306A4 (en) 2013-04-18 2016-12-07 Armo Biosciences Inc Methods of using interleukin-10 for treating diseases and disorders
CA2914837A1 (en) 2013-06-17 2014-12-24 Armo Biosciences, Inc. Method for assessing protein identity and stability
JP6660297B2 (en) 2013-11-11 2020-03-11 アルモ・バイオサイエンシーズ・インコーポレイテッド Methods of using interleukin-10 to treat diseases and disorders
CN103920114B (en) * 2014-03-31 2017-01-18 李树民 Traditional Chinese medicinal composition for treating pulmonary fibrosis
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
JP6675394B2 (en) 2014-10-22 2020-04-01 アルモ・バイオサイエンシーズ・インコーポレイテッド Use of interleukin-10 for the treatment of diseases and disorders
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20190290733A1 (en) * 2015-03-11 2019-09-26 Nektar Therapeutics Conjugates of an il-7 moiety and a polymer
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
EP3341012A4 (en) 2015-08-25 2019-03-20 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032396A (en) * 1989-02-17 1991-07-16 Immunex Corporation IL-7 to stimulate platelet production

Also Published As

Publication number Publication date
AU2002307497A1 (en) 2002-11-05
WO2002085300A2 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
WO2002085300A3 (en) Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
DK1812440T3 (en) Pyrazolo [1,5-a] pyrimidines which can be used as inhibitors of protein kinases
TW200607803A (en) Pyrrole inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
ATE365733T1 (en) COMPOSITIONS USEFUL AS PROTEIN KINASE INHIBITORS
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
TW200633980A (en) Pyridones useful as inhibitors of kinases
CY1112253T1 (en) DIOMINOTRIZOL COMPOUNDS USEFUL AS PROTEIN MOTOR SUSPENSIONS
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
CY1112238T1 (en) ANTI-KINESIN SUSPENSIONS AND METHODS OF USING THESE
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
NO20074431L (en) Pyrrolopyrimidines useful as protein kinase inhibitors
NO20041917L (en) Specific agents that bind human angiopoietin-2
WO2003094617A3 (en) Use of vegf for treating bone defects
WO2004084835A3 (en) Treating immunological disorder using agonists of interleukin-21/ interleukin-21 receptor
SI1789398T1 (en) 2-amino-quinazoline derivatives useful as inhibitors of b-secretase (bace)
WO2005056547A3 (en) Quinoxalines useful as inhibitors of protein kinases
EA200501690A1 (en) COMPOSITION INCLUDING PDE4 INHIBITOR AND PDE5 INHIBITOR
ATE389651T1 (en) PYRROLE COMPOSITIONS SUITABLE AS INHIBITORS OF C-MET
SI1404304T1 (en) Tablet comprising cetirizine and pseudoephedrine
CY1109666T1 (en) METHOD OF THERAPEUTIC AND RACOIDIS DISEASE TREATMENT
WO2004081229A3 (en) Use of bv8 and/or eg-vegf to promote hematopoiesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP